H. Gogas

H. Gogas, C. Markopoulos, N. Givalos, 1998, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Advances and trends in dermato-oncology

H. Gogas, A. Stratigos, C. Dessinioti, 2010, Expert review of anticancer therapy.

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS).

D. Schadendorf, K. Flaherty, P. Ascierto, 2021, European journal of cancer.

Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer

M. Dimopoulos, H. Gogas, G. Fountzilas, 2015, Supportive Care in Cancer.

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

P. Ascierto, A. Arance, P. Queirolo, 2022, European journal of cancer.

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus.

M. Del Vecchio, H. Gogas, L. Demidov, 2022, European journal of cancer.

Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam).

H. Gogas, J. Mansi, F. Lofts, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group

K. Syrigos, V. Georgoulias, H. Gogas, 2021, Cancer Immunology, Immunotherapy.

Nivolumab in previously untreated melanoma without BRAF mutation.

D. Schadendorf, K. Savage, C. Horak, 2015, The New England journal of medicine.

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

D. Schadendorf, K. Savage, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.

H. Gogas, A. Stratigos, P. Diamantopoulos, 2018, Journal of immunotherapy.

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.

N. Pavlidis, H. Gogas, G. Fountzilas, 2007, Anticancer research.

Multichamber Involvement of Metastatic Cardiac Melanoma

H. Gogas, J. Barbetseas, C. Kapelios, 2022, Diagnostics.

CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters

E. Evangelou, H. Gogas, L. Pappas, 2018, Acta dermato-venereologica.

Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.

H. Gogas, E. Kassi, P. Diamantopoulos, 2017, Melanoma research.

Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapy—A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study

A. Charchanti, H. Gogas, G. Aravantinos, 2022, Cancers.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk associations of melanoma in a Southern European population: results of a case/control study

H. Gogas, A. Hatzakis, A. Stratigos, 2008, Cancer Causes & Control.

Evaluation of self-assessed melanoma growth rate in a Mediterranean patient population.

H. Gogas, E. Gagari, A. Stratigos, 2011, Melanoma research.

Evaluation of IL-10 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.

H. Gogas, G. Fountzilas, D. Pectasides, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial

K. Flaherty, A. Arance, H. Gogas, 2019, Annals of Oncology.

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

H. Gogas, J. Haanen, D. Ziogas, 2022, Cancer treatment reviews.

Docetaxel in Combination with Dacarbazine in Patients with Advanced Melanoma

H. Gogas, G. Fountzilas, G. Samonis, 2002, Oncology.

Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma

C. Berking, D. Schadendorf, K. Flaherty, 2017 .

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)

P. Ascierto, J. Larkin, A. Arance, 2017 .

Nonmelanoma skin tumors involving the craniofacial region: our 22 years of experience.

H. Gogas, A. Kostakis, P. Konofaos, 2007, The Journal of craniofacial surgery.

Biomarkers in melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience

H. Gogas, D. Dimitroulis, C. Damaskos, 2018, AntiCancer Research.

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.

H. Gogas, H. Kalofonos, G. Fountzilas, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

G. Fountzilas, N. Pavlidis, H. Gogas, 2012, Cancer Chemotherapy and Pharmacology.

19p13.1 is a triple-negative-specific breast cancer susceptibility locus.

Daniel J. Park, Julian Peto, Kamila Czene, 2012, Cancer research.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

A. Hauschild, P. Ascierto, J. Larkin, 2014, The Lancet. Oncology.

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.

N. Pavlidis, H. Gogas, R. Wirtz, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.

H. Gogas, P. Diamantopoulos, Amalia Anastasopoulou, 2017, Journal of immunotherapy.

A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.

H. Gogas, A. Stratigos, C. Dessinioti, 2019, The oncologist.

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

H. Gogas, D. Ziogas, M. Theochari, 2021, American Journal of Clinical Dermatology.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2018, The Lancet. Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Mucosal melanoma of the head and neck.

G. Botti, P. Ascierto, G. Gatta, 2017, Critical reviews in oncology/hematology.

Next generation of immunotherapy for melanoma.

J. Kirkwood, H. Zarour, L. Butterfield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium

S. Puig, M. Tucker, K. Peris, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

Melanuria in a patient with BRAF-mutant metastatic melanoma of unknown primary: Insights on the pathophysiology, differential diagnosis, prognosis, and treatment.

H. Gogas, P. Diamantopoulos, Emmanouil Charakopoulos, 2022, The American journal of the medical sciences.

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

C. Berking, D. Schadendorf, J. Becker, 2015, European journal of cancer.

A study of a single variant allele (rs1426654) of the pigmentation‐related gene SLC24A5 in Greek subjects

H. Gogas, A. Stratigos, A. Katsambas, 2009, Experimental dermatology.

Melanoma immunotherapy dominates the field.

H. Gogas, P. Diamantopoulos, 2016, Annals of translational medicine.

Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.

H. Gogas, A. Papalambros, E. Felekouras, 2022, Critical reviews in oncology/hematology.

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy

E. Cholongitas, H. Gogas, J. Haanen, 2020, Journal for ImmunoTherapy of Cancer.

Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials.

H. Gogas, A. Polyzos, Aristeidis G. Vaiopoulos, 2014, Cancer letters.

p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants

H. Gogas, C. Antoniou, A. Stratigos, 2007, The British journal of dermatology.

Prognostic significance of autoimmunity during treatment of melanoma with interferon

J. Kirkwood, H. Gogas, A. Tarhini, 2006, Seminars in Immunopathology.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

H. Gogas, G. Aravantinos, A. Psyrri, 2016, Journal of Translational Medicine.

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

M. Dimopoulos, E. Giannoulatou, H. Gogas, 2016, Oncotarget.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

A. McKenna, K. Cibulskis, S. Gabriel, 2014, Cancer discovery.

Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials

H. Gogas, A. Marshall, G. Fountzilas, 2015, Cancer medicine.

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

K. Flaherty, J. Larkin, H. Gogas, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

A. Regev, J. Utikal, S. Haferkamp, 2019, Nature Medicine.

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients

S. Ringquist, L. Butterfield, H. Gogas, 2015, PloS one.

Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer

E. Giannoulatou, H. Gogas, G. Lazaridis, 2019, Cancer Genomics & Proteomics.

Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance

H. Gogas, M. Koutsilieris, A. Nezos, 2009, Clinical chemistry and laboratory medicine.

COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma

A. Hauschild, K. Flaherty, J. Larkin, 2014 .

New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.

H. Gogas, E. Lakiotaki, P. Diamantopoulos, 2020, Melanoma research.

Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.

H. Gogas, G. Aravantinos, G. Fountzilas, 2016, Anticancer research.

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

F. Fostira, D. Yannoukakos, H. Gogas, 2017, American journal of cancer research.

Significance of survivin mRNA blood levels in patients with melanoma.

H. Gogas, G. Papaxoinis, P. Diamantopoulos, 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial

George Fountzilas, Christos Christodoulou, George Kouvatseas, 2012, Breast Cancer Research.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

P. Ascierto, H. Gogas, P. Rutkowski, 2020, The Lancet.

Full Dose Paclitaxel Plus Vinorelbine as Salvage Chemotherapy in Anthracycline-Resistant Advanced Breast Cancer: A Phase II Study

G. Kouraklis, G. Kouraklis, H. Gogas, 2003, Journal of chemotherapy.

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

D. Schadendorf, P. Ascierto, E. Lipson, 2021 .

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, European journal of cancer.

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

A. Regev, J. Utikal, S. Haferkamp, 2019, Nature Medicine.

Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score.

John P A Ioannidis, George M Spyrou, Evangelos Evangelou, 2016, The Journal of investigative dermatology.

Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View

H. Gogas, A. Polyzos, P. Diamantopoulos, 2020 .

Immunotherapy for advanced melanoma: fulfilling the promise.

J. Kirkwood, H. Gogas, A. Polyzos, 2013, Cancer treatment reviews.

Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy

U. Dafni, H. Gogas, V. Kyriakou, 2008, Oncology.

Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review

H. Gogas, P. Papalexis, D. Ziogas, 2022, Experimental and therapeutic medicine.

Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review.

A. Hauschild, P. Ascierto, H. Gogas, 2013, Critical reviews in oncology/hematology.

Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma

A. Hauschild, J. Kirkwood, A. Testori, 2008, Cancer.

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel

M. Dimopoulos, U. Dafni, H. Gogas, 2012, PloS one.

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

M. Dimopoulos, U. Dafni, H. Gogas, 2012, Breast Cancer Research and Treatment.

Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”

F. Marincola, P. Ascierto, G. Ciliberto, 2013, Journal of translational medicine.

H. Gogas, R. Wirtz, G. Fountzilas, 2012, Breast Cancer Research.

Emergency Surgery for Metastatic Melanoma

G. Kouraklis, H. Gogas, D. Mantas, 2014, International journal of surgical oncology.

Chemotherapy for metastatic melanoma

V. Sondak, J. Kirkwood, H. Gogas, 2007, Cancer.

Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

M. Dimopoulos, H. Gogas, G. Lazaridis, 2018, PloS one.

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

P. Ascierto, H. Gogas, D. Ziogas, 2021, Frontiers in Oncology.

Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer

S. Giannouli, H. Gogas, A. Psyrri, 2019, AntiCancer Research.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, The Lancet. Oncology.

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies

H. Gogas, G. Fountzilas, G. Pentheroudakis, 2014, BMC Clinical Pathology.

Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17

H. Gogas, C. Papadimitriou, G. Aravantinos, 2014, PloS one.

Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial.

N. Uzunoglu, H. Gogas, C. Dardoufas, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dirk Schadendorf, Reinhard Dummer, Naoya Yamazaki, 2018, The Lancet. Oncology.

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

H. Gogas, D. Cunningham, T. Skov, 2002, British Journal of Cancer.

Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B

M. Mihm, H. Gogas, G. Paterakis, 2002, American journal of clinical oncology.

Glycogen-rich clear cell carcinoma of the breast

H. Gogas, C. Markopoulos, Z. Antonopoulou, 2008, World journal of surgical oncology.

Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes.

H. Gogas, C. Markopoulos, N. Tsavaris, 2009, Anticancer research.

Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group.

H. Gogas, C. Markopoulos, T. Economopoulos, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.

A. Adamou, H. Gogas, G. Fountzilas, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Meeting report from the “ Melanoma Research : a bridge from Naples to the World . Napoli , December 5 th – 6 th 2011 ”

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers

B. Monk, A. Jazaeri, A. Jimeno, 2021, Journal for ImmunoTherapy of Cancer.

Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes

E. Giannoulatou, H. Gogas, G. Lazaridis, 2016, Breast Cancer Research and Treatment.

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study

H. Gogas, G. Aravantinos, K. Papadopoulou, 2015, PloS one.

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon

F. Marincola, J. Kirkwood, H. Gogas, 2012, PloS one.

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

M. Dimopoulos, U. Dafni, H. Gogas, 2009, Breast Cancer Research and Treatment.

Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)

H. Gogas, G. Fountzilas, D. Skarlos, 2004, Cancer investigation.

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

H. Gogas, G. Fountzilas, D. Skarlos, 2003, Clinical breast cancer.

Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.

H. Gogas, D. Tsoutsos, M. Mantzourani, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin--vinblastine--temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG).

H. Gogas, G. Fountzilas, G. Pentheroudakis, 2015, Anticancer research.

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

U. Dafni, H. Gogas, G. Fountzilas, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report

P. Ascierto, E. Cholongitas, H. Gogas, 2020, Journal for ImmunoTherapy of Cancer.

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials

M. Dimopoulos, U. Dafni, N. Pavlidis, 2013, BMC Cancer.

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

H. Gogas, R. Wirtz, G. Aravantinos, 2012, Journal of Translational Medicine.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

A. Hauschild, P. Ascierto, J. Larkin, 2019, European journal of cancer.

Methods of detection of circulating melanoma cells: a comparative overview.

H. Gogas, M. Koutsilieris, A. Katsambas, 2011, Cancer treatment reviews.

Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.

A. Enk, M. Weichenthal, A. Hauschild, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

D. Schadendorf, B. Schilling, A. Gesierich, 2019, Cancer Immunology, Immunotherapy.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

A. Hauschild, R. Dummer, K. Peris, 2018, European journal of cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

H. Gogas, R. Wirtz, G. Aravantinos, 2015, Journal of Translational Medicine.

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group

H. Gogas, C. Markopoulos, G. Fountzilas, 2005, Breast Cancer Research and Treatment.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

N. Pavlidis, H. Gogas, R. Wirtz, 2009, Breast Cancer Research and Treatment.

Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial

H. Gogas, C. Papadimitriou, C. Markopoulos, 2022, British Journal of Cancer.

RT-PCR for tyrosinase expression as a molecular marker in malignant melanoma.

H. Gogas, G. Kefala, 2002, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Prognostic significance of the sequential detection of circulating melanoma cells by RT–PCR in high-risk melanoma patients receiving adjuvant interferon

H. Gogas, D. Pectasides, A. Polyzos, 2002, British Journal of Cancer.

Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study

H. Gogas, E. Petridou, G. Fountzilas, 2012, European Journal of Epidemiology.

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, Journal of Clinical Oncology.

The role of taxanes in the treatment of metastatic melanoma

H. Gogas, A. Bedikian, D. Bafaloukos, 2004, Melanoma research.

Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.

H. Gogas, G. Fountzilas, D. Skarlos, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide i n C ombination W ith D ocetaxel i n P atients With A dvanced M elanoma: A P hase I I S tudy o f t he Hellenic C ooperative O ncology G roup

H. Gogas, G. Fountzilas, P. Kosmidis, 2002 .

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

P. Ascierto, M. Del Vecchio, I. Krajsová, 2021, Cancers.

Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma

H. Gogas, D. Ziogas, Frosso Konstantinou, 2020, Expert review of anticancer therapy.

Adjuvant Systemic Therapy for High-Risk Melanoma Patients

V. Sondak, Y. Najjar, J. Kirkwood, 2018, Cutaneous Melanoma.

Advances in adjuvant therapy: potential for prognostic and predictive biomarkers.

D. Davar, J. Kirkwood, H. Gogas, 2014, Methods in molecular biology.

H. Gogas, E. Kassi, G. Papaxoinis, 2019, Cancer medicine.

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

J. Utikal, D. Schadendorf, B. Schilling, 2017, Nature Communications.

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.

I. Zalaudek, A. Hauschild, R. Dummer, 2017, European journal of cancer.

Treatment Algorithms in Stage IV Melanoma

A. Hauschild, D. Schadendorf, R. Dummer, 2015, American journal of therapeutics.

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study

George Fountzilas, Anastasia G. Eleftheraki, George Pentheroudakis, 2011, Breast Cancer Research and Treatment.

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

R. Karls, A. Lallas, J. Paoli, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Role of CXCL13 and CXCL9 in Early Breast Cancer.

H. Gogas, R. Wirtz, K. Pavlakis, 2019, Clinical breast cancer.

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy

M. Dimopoulos, H. Gogas, R. Wirtz, 2018, Cancer medicine.

Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy

H. Gogas, R. Wirtz, C. Markopoulos, 2017, Translational oncology.

Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group

H. Gogas, R. Wirtz, G. Lazaridis, 2017, Journal of Translational Medicine.

Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study

H. Gogas, R. Wirtz, G. Lazaridis, 2016, PloS one.

Endometrioid carcinoma arising in a scar of caesarean section. Case report.

H. Gogas, C. Markopoulos, G. Eleftheriou, 1996, European journal of gynaecological oncology.

Clinical experience of using Oncotype DX as an additional treatment decision tool in early breast cancer - a retrospective analysis from 5 Greek institutions.

H. Gogas, C. Markopoulos, Z. Antonopoulou, 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy

U. Dafni, H. Gogas, C. Markopoulos, 2009, Breast Cancer Research.

Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline‐Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials

H. Gogas, G. Aravantinos, G. Fountzilas, 2017, Clinical breast cancer.

Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer

H. Gogas, H. Kalofonos, G. Fountzilas, 2009, Oncology.

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature

H. Gogas, D. Ziogas, N. Viniou, 2020, Therapeutic advances in medical oncology.

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes

E. Giannoulatou, H. Gogas, G. Aravantinos, 2016, PloS one.

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2019, European journal of cancer.

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection

K. Syrigos, H. Gogas, G. Magiorkinis, 2021, Vaccines.

Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.

H. Gogas, T. Economopoulos, E. Kastritis, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study.

H. Gogas, G. Chalkiadakis, C. Ioannou, 2010, Oncology reports.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

P. Ascierto, M. Del Vecchio, M. Mandalà, 2021, Journal for ImmunoTherapy of Cancer.

Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.

H. Gogas, H. Linardou, D. Bafaloukos, 2019, Melanoma research.

The Role of Sentinel Lymph Node Biopsy in Thin Melanoma (Breslow Thickness ≤ 0.75 mm and 0.76 mm - 1.0 mm Respectively): Our Results and Review of the Literature

H. Gogas, G. Kechagias, D. Tsoutsos, 2016 .

Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).

P. Ascierto, R. Dummer, J. Larkin, 2018 .

Hamartomas of the breast.

H. Gogas, C. Markopoulos, J. Gogas, 1994, The American surgeon.

Mucoepidermoid carcinoma of the breast.

H. Gogas, C. Markopoulos, D. Floros, 1998, European Journal of Gynaecological Oncology.

Cavernous haemangioma of the breast. A case report.

H. Gogas, C. Markopoulos, V. Kyriakou, 1998, European journal of gynaecological oncology.

Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen

H. Gogas, D. Ziogas, Aikaterini Katsandris, 2021, Expert Review of Precision Medicine and Drug Development.

Malignant melanoma of the stomach presenting with an unknown primary lesion

H. Gogas, D. Tsoutsos, J. Ioannovich, 2003, European Journal of Plastic Surgery.

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

D. Schadendorf, P. Ascierto, P. Queirolo, 2021, Clinical Trials.

Diagnosis and Treatment of Intracystic Breast Carcinomas

H. Gogas, C. Markopoulos, E. Kouskos, 2002, The American surgeon.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

Metastatic Melanoma in the Gallbladder: Report of a Case

H. Gogas, C. Markopoulos, E. Kouskos, 2003, Surgery Today.

Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

H. Gogas, C. Markopoulos, G. Fountzilas, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.

P. Ascierto, J. Schachter, H. Gogas, 2022, Journal of Clinical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019 .

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2018 .

Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.

G. Chrousos, H. Gogas, E. Petridou, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials.

A. Hauschild, D. Schadendorf, K. Flaherty, 2017, European journal of cancer.

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

F. Fostira, D. Yannoukakos, H. Gogas, 2009, British Journal of Cancer.

Melanocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population.

H. Gogas, A. Hatzakis, A. Stratigos, 2006, The Journal of investigative dermatology.

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy

H. Gogas, G. Magiorkinis, E. Solomou, 2022, Cancers.

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)

M. Dimopoulos, N. Pavlidis, H. Gogas, 2013, PloS one.

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

J. Kirkwood, H. Gogas, A. Tarhini, 2011, Seminars in immunopathology.

Cardiotoxicity after vemurafenib administration.

D. Tousoulis, H. Gogas, K. Toutouzas, 2019, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

U. Dafni, H. Gogas, V. Kyriakou, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative

E. Giannoulatou, H. Gogas, Jianhua Zhang, 2020, Oncotarget.

Effect of aromatase inhibitors on the lipid profile of postmenopausal breast cancer patients

H. Gogas, C. Markopoulos, A. Tsaroucha, 2010 .

Circulating adiponectin levels in relation to melanoma: a case-control study.

C. Mantzoros, G. Chrousos, H. Gogas, 2007, European journal of cancer.

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2021 .

Expression of p 27 KIP 1 , p 21 WAF 1 and p 53 does Not Correlate with Prognosis in Node-negative Invasive Ductal Carcinoma of the Breast

K. Kyriakou, A. Adamou, H. Gogas, 2008 .

Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.

K. Kyriakou, A. Adamou, H. Gogas, 2006, Anticancer research.

Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.

H. Gogas, R. Wirtz, K. Pavlakis, 2015, Anticancer research.

Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center

K. Spiliopoulos, H. Gogas, G. Papaxoinis, 2018, Melanoma research.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

M. Dimopoulos, U. Dafni, N. Pavlidis, 2014, BMC Cancer.

Inhibition of the Hedgehog pathway in lung cancer.

H. Gogas, K. Syrigos, A. Bamias, 2019, Lung cancer.

The role of depression and personality traits in patients with melanoma: a South-European study

H. Gogas, E. Petridou, N. Dessypris, 2017, Melanoma research.

Unusual radiological findings in a case of myelofibrosis secondary to polycythemia vera

H. Gogas, G. Vaiopoulos, M. Kanakis, 2006, Annals of Hematology.

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.

M. Dimopoulos, U. Dafni, H. Gogas, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

IFN-λ cancer immunotherapy: new kid on the block.

J. Kirkwood, H. Gogas, A. Lasfar, 2016, Immunotherapy.

Melanoma: the radiotherapeutic point of view; review of the current literature.

H. Gogas, K. Mystakidou, A. Zygogianni, 2011, Reviews on recent clinical trials.

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events

H. Gogas, P. Papalexis, D. Ziogas, 2023, Cancers.

Pre-operative Tc-99m-Sestamibi Scanning and Intra-Operative Nuclear Mapping: Are they Accurate In Localizing Parathyroid Adenomas ?

H. Gogas, C. Markopoulos, E. Kouskos, 2003, Acta chirurgica Belgica.

1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

M. Zhou, H. Gogas, C. Lebbé, 2022, Late-Breaking Abstracts.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial

N. Pavlidis, H. Gogas, R. Wirtz, 2012, Cancer Chemotherapy and Pharmacology.

Relationship of epidermal growth factor receptor (EGFR), proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients

C. Kandaraki, H. Gogas, J. Gogas, 1995, Cytopathology : official journal of the British Society for Clinical Cytology.

Severe thrombocytopenia related to trastuzumab infusion

H. Gogas, M. Mantzourani, J. Meletis, 2011, Medical science monitor : international medical journal of experimental and clinical research.

Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose–dense sequential adjuvant chemotherapy

M. Dimopoulos, H. Gogas, C. Markopoulos, 2006, Breast Cancer Research and Treatment.

Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial

H. Gogas, C. Markopoulos, D. Koukouras, 2012, Journal of Cancer Research and Clinical Oncology.

Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.

H. Gogas, E. Felekouras, C. Tsigris, 2009, Anticancer research.

Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.

G. Kouraklis, H. Gogas, J. Griniatsos, 2007, Anticancer research.

Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?

H. Gogas, C. Markopoulos, G. Fountzilas, 2020, Cancer Immunology, Immunotherapy.

Outpatient treatment with epirubicin and oral etoposide in patients with small-cell lung cancer.

H. Gogas, J. Mansi, T. Evans, 1997, British Journal of Cancer.

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

D. Schadendorf, J. Malvehy, H. Gogas, 2021, Journal for ImmunoTherapy of Cancer.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women

N. Pavlidis, H. Gogas, H. Kalofonos, 2006, Breast Cancer Research and Treatment.

Hypercalcemia of malignancy treated with cinacalcet

H. Gogas, E. Kassi, Nikolaos Asonitis, 2017, Endocrinology, diabetes & metabolism case reports.

The prevalence of autoantibodies in patients with high risk melanoma receiving adjuvant interferon

H. Gogas, I. Potouridou, A. Stratigos, 2004 .

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

H. Gogas, D. Ziogas, C. Theocharopoulos, 2023, Cancers.

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials

H. Gogas, G. Aravantinos, A. Psyrri, 2015, Oncotarget.

Mitoxantrone Plus Vinorelbine in Pretreated Patients with Metastatic Breast Cancer

H. Gogas, C. Markopoulos, G. Fountzilas, 2007, Journal of chemotherapy.

Mitoxantrone Plus Gemcitabine in Pretreated Patients with Metastatic Breast Cancer

H. Gogas, C. Markopoulos, H. Kalofonos, 2006, Journal of chemotherapy.

Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer.

M. Dimopoulos, N. Pavlidis, H. Gogas, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials

J. Malvehy, H. Gogas, R. Gutzmer, 2018, Annals of Oncology.

Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas

H. Gogas, D. Ziogas, S. Karamaroudis, 2023, Oncology research.

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature

H. Gogas, M. Dimopoulou, P. Diamantopoulos, 2023, Therapeutic advances in hematology.

Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes

H. Gogas, Anastasios Stofas, G. Fountzilas, 2014, PloS one.

BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.

D. Schadendorf, L. Garraway, J. Sosman, 2015 .

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer

H. Gogas, G. Aravantinos, A. Psyrri, 2016, Journal of Translational Medicine.

The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature

H. Gogas, D. Ziogas, G. Liapis, 2021, Therapeutic advances in medical oncology.

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies

H. Gogas, J. Haanen, D. Ziogas, 2023, Open forum infectious diseases.

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

H. Gogas, D. Ziogas, M. Samarkos, 2021, Vaccines.

Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

D. Schadendorf, P. Ascierto, E. Lipson, 2022, Journal of Clinical Oncology.

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study.

H. Gogas, C. Markopoulos, A. Michailidou, 2004, Journal of Clinical Oncology.

Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.

N. Pavlidis, H. Gogas, R. Wirtz, 2012, Clinical breast cancer.

D. Schadendorf, E. Lipson, H. Tawbi, 2023, European journal of cancer.

Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer

E. Giannoulatou, H. Gogas, G. Aravantinos, 2020, Cancer Genomics & Proteomics.

Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer

H. Gogas, G. Aravantinos, H. Kalofonos, 2007, Medical oncology.

Expanded access programmes: patient interests versus clinical trial integrity.

A. Hauschild, D. Schadendorf, V. Sondak, 2015, The Lancet. Oncology.

The effect of exemestane on the lipidemic profile of breast cancer patients: Preliminary results of the TEAM trial Greek sub-study

H. Gogas, C. Markopoulos, A. Michailidou, 2004 .

Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

M. Dimopoulos, H. Gogas, G. Aravantinos, 2016, Clinical breast cancer.

Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival

M. Dimopoulos, N. Pavlidis, H. Gogas, 2006, Breast Cancer Research and Treatment.

Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus

Xiaoqing, Daniel J. Park, Arif, 2012 .

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2021, Annals of Oncology.

PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

D. Schadendorf, P. Ascierto, G. Boland, 2022, Future oncology.

A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon

J. Kirkwood, H. Gogas, C. Markopoulos, 2014, PloS one.

Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).

D. Schadendorf, P. Ascierto, R. Dummer, 2017 .

Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.

H. Gogas, D. Fennelly, 1996, Gynecologic oncology.

Future Perspectives in melanoma research. Meeting report from the Research: a to

A. Hauschild, K. Flaherty, P. Ascierto, 2012 .

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

H. Gogas, R. Wirtz, G. Aravantinos, 2015, Journal of Translational Medicine.

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

D. Schadendorf, P. Ascierto, E. Lipson, 2023, NEJM Evidence.

Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).

A. Enk, M. Weichenthal, A. Hauschild, 2008 .

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

A. Hauschild, D. Schadendorf, P. Ascierto, 2019, European journal of cancer.

1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

P. Ascierto, J. Larkin, M. Mandalà, 2020 .

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.

D. Schadendorf, P. Ascierto, E. Lipson, 2023, Journal of Clinical Oncology.

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.

N. Pavlidis, H. Gogas, G. Fountzilas, 2003, Lung cancer.

Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatin.

G. Kouraklis, H. Gogas, J. Griniatsos, 2006, Anticancer research.

Reply to P. Mohr et al

U. Dafni, H. Gogas, D. Pectasides, 2009 .

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2017 .

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

H. Gogas, J. Grob, L. Demidov, 2021 .

Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with 153Sm-EDTMP

H. Gogas, E. Kassi, M. Kokkinos, 2017, BMJ Case Reports.

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

D. Schadendorf, B. Schilling, A. Gesierich, 2019, Cancer Immunology, Immunotherapy.

Prognostic significance of autoimmunity during treatment of melanoma with interferon

J. Kirkwood, H. Gogas, A. Tarhini, 2006, Seminars in Immunopathology.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

A. Hauschild, G. Linette, J. Kirkwood, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.

N. Pavlidis, H. Gogas, R. Wirtz, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The Rapidly Changing Landscape of Advanced-Stage Melanoma Treatment and Its Implications for New Drug Development

V. Sondak, H. Gogas, Mark R. Middleton, 2012 .

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

P. Ascierto, M. Sznol, H. Gogas, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granular cell tumor of the breast: a rare lesion resembling breast cancer.

H. Gogas, C. Markopoulos, E. Kouskos, 2002, European journal of gynaecological oncology.

Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy

H. Gogas, I. Delladetsima, M. Perdiki, 2017, Cancer Investigation.

Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with BRAFV600+melanoma.

P. Ascierto, H. Gogas, P. Rutkowski, 2020, Journal of Clinical Oncology.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

D. Mallardo, P. Ascierto, M. Del Vecchio, 2024, Nature communications.

Prevalence of BRCA1 mutations among 284 women with triple-negative breast cancer.

F. Fostira, D. Yannoukakos, H. Gogas, 2010 .